Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 2
Treatment-assignment count: 0
Stratification count: 0
Low Public Signal
PD-L1 expression
melanoma · Monoclonal Antibody
PD-L1 expression is flagged as low public signal because public trials show inclusion required evidence in 5 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 2
Common snippets: MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03597282 | https://clinicaltrials.gov/study/NCT04773951 | https://clinicaltrials.gov/study/NCT05483400 | https://clinicaltrials.gov/study/NCT07586891 | https://clinicaltrials.gov/study/NCT03086174